Xolair
Anti-IgE therapy for chronic urticaria that no longer answers antihistamines.
Xolair (omalizumab) binds free IgE and lowers the mast-cell reactivity behind chronic spontaneous urticaria — daily hives, deep swelling and relentless itch. It is an established option when appropriately increased doses of second-generation antihistamines do not adequately control symptoms.
- Injection
- Route
- 4 weekly
- Interval
- 2–8 wks
- First results
- Free IgE
- Target
- Urticaria activity scoring
- Trigger and drug review
- Monthly injection
- Steroid-sparing plan
Diagnosed first, treated second.
Because urticaria is often mistaken for allergy, treatment begins with a proper differential: thyroid function, autoimmune markers, physical triggers and medication review. For chronic spontaneous urticaria, dosing is commonly every four weeks, with the schedule and duration set by the prescriber and response tracked using a symptom score.
- 01Urticaria activity scoring
- 02Trigger and drug review
- 03Monthly injection
- 04Steroid-sparing plan
- 05Structured taper
- Hives persisting beyond six weeks
- No control on high-dose antihistamines
- Recurrent angioedema
- Repeated courses of oral steroids
- Significant sleep or quality-of-life impact
How the treatment works
A sequence, not a single appointment — each step informs the next.
- 01
Diagnosis
Urticaria activity scoring, trigger review and bloodwork to exclude mimics and drivers.
- 02
Antihistamine optimisation
Confirming the ceiling of conventional therapy before biologics are introduced.
- 03
Monthly dosing
Subcutaneous injection in clinic every four weeks, with observation after early doses.
- 04
Review
Activity scores at each visit; dose interval and duration adjusted on symptom control.
Results measured, not promised.
What to expect
- 01Fewer hive episodes within the first month
- 02Marked reduction in itch and night waking
- 03Less angioedema and facial swelling
- 04Lower reliance on oral steroids
- 05Some patients achieve complete symptom control
Results, treatment timing and recovery vary by diagnosis and individual factors. This page is educational and does not replace a medical consultation or guarantee an outcome. Prescription treatment is selected after reviewing current product information, approved indications, infection and vaccination history, other medicines and drug-specific risks.
Begin with a diagnosis,
not a guess.
Share a few details and the clinic will reply with available consultation times for xolair — one-to-one with Dr. Arely.
- Response
- Within 24 hours
- Consultation
- One-to-one, 45 min
- Assessment
- Trichoscopy included
- Location
- Dr. Arely Clinic
Frequently asked
Usually not. Most cases are autoimmune or spontaneous, which is why avoidance diets rarely resolve them.
A minimum of six months is typical, then a planned taper once control is stable.
Some patients relapse and resume treatment; many remain in remission after a supervised taper.
Xolair carries a boxed warning for anaphylaxis, which can occur after any dose. Administration setting, observation and possible self-injection are decided after an individual risk assessment.